Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2001

View Archived Issues

Graft material for oral mucosal defects

Orion and Pharmacia agree to develop antianxiety treatment for the U.S. market

CollaGenex to market dental products from Atrix in the U.S.

CV Therapeutics and Incyte advance cardiovascular genomics collaboration

Avant replies to FDA's clinical hold of TP-10

Novel inhibitors of human CD23 and TNF release reported by GSK

Four centers added to Neotrofin Parkinson's disease trial

PH-10 enters phase I study for treatment of actininc keratosis

OSI Pharmaceuticals updates Tarceva development

Exisulind reduces adenomatous colon polyps in clinical trial

Virax to develop prostate cancer immunotherapy

More data reported for BMP delivery systems

Adult skin as a source of multipotent stem cells

NeoGenesis to develop drug leads for Mitsubishi-Tokyo Pharmaceuticals

BTG takes over development of oral vaccine delivery technology

Affymetrix and Orchid broaden genetic technology alliance

Positive phase II results reported for PhotoCure's Hexvix diagnostic

Pharmacia presents antiherpesvirus agents with outstanding activity at ACS

Corgentech cleared by FDA to begin phase III trial of E2F decoy

NeuroSearch cleared to begin phase I studies of potential sickle cell disease treatment in U.S.

ImmunoGen highlights significant events over past year

GSK describes NPY Y5 antagonists and their effect on food intake

Banyu describes first M3 antagonist with high selectivity over other muscarinic subtypes

Meiji Seika discloses new antineoplastics isolated from fungus

Dual angiotensin/endothelin receptor antagonists reported by BMS

CRF antagonists added to DuPont patent portfolio

Research at Nippon Shinyaku leads to new antitumor compounds

Novel DMARDs reported by Sumitomo during the ACS meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...